Medmix Ltd
SIX:MEDX
Medmix Ltd
medmix AG designs, develops and produces delivery devices for the mixing, application and injection of liquids for the healthcare, consumer and industrial end-markets. The company is headquartered in Zug, Zug and currently employs 2,101 full-time employees. The firm operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
medmix AG designs, develops and produces delivery devices for the mixing, application and injection of liquids for the healthcare, consumer and industrial end-markets. The company is headquartered in Zug, Zug and currently employs 2,101 full-time employees. The firm operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
Record Revenue: medmix achieved record group revenue in 2023, with growth in Consumer & Industrial segments offsetting declines in Healthcare due to Dental destocking.
Profitability: Adjusted EBITDA margin was 19.1%, in line with revised guidance, but down year-on-year due to product mix and higher industry costs.
Cash Flow: Adjusted operating net cash flow increased 9% year-on-year, despite significant capital expenditure.
2024 Outlook: Management expects 4–6% organic revenue growth and an adjusted EBITDA margin of at least 20%, with improvements skewed to the second half as Dental and Industry recover.
Strategic Progress: The new Industry plant in Spain is fully operational; Healthcare plant in Atlanta is on track. Acquisition of Qiaoyi boosts Beauty segment and Asian presence.
Dental Recovery: Dental market expected to normalize mid-2024 as destocking stabilizes and end-market demand persists.
Innovation: Several new sustainable and user-focused products were launched, supporting future growth.
